R&D Trends

Dow AgroSciences, TeselaGen expanding advanced biodesign platform for Ag

Monday, August 28, 2017

Innovative use of molecular design technology is essential for discovering and developing new agricultural products at a faster pace. TeselaGen Biotechnology, and Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical, announced they have entered a new phase in their collaboration to produce a state-of-the-art biological design automation platform that can speed discovery work. The companies began collaborating in 2016.

[Read More]

Topas Therapeutics, Eli Lilly ink agreement on immune tolerance

Friday, August 25, 2017

Topas Therapeutics, a Hamburg, Germany-based private company, has signed a multi-year agreement with Eli Lilly to collaborate in the field of antigen-specific tolerance induction with an initial focus on external antigens thought to induce inflammation and/or autoimmune disease. Topas will be responsible for conducting pre-clinical proof-of-principle studies in collaboration with Lilly to generate drug candidates. Under the terms of the agreement, Lilly has an option for all candidates produced under the collaboration for in-licensing and further development. Topas will receive R&D funding and participate in the future success of any compounds in-licensed by Lilly. Financial details of the collaboration are not being disclosed.

[Read More]

CRISPR, Massachusetts General Hospital partner on CRISPR/Cas9 in T cell cancer therapies

Thursday, August 24, 2017

CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Massachusetts General Hospital Cancer Center (MGHCC), a scientific and clinical institution, have entered into a two-year research collaboration and license option agreement to develop novel T cell therapies for cancer. As part of the collaboration, CRISPR/Cas9 gene editing will be utilized to improve upon current T cell therapies in development, ultimately addressing unmet needs in both hematologic and solid tumors. Marcela V. Maus, M.D., Ph.D., director of the Cellular Immunotherapy Program at MGHCC and Assistant Professor of Medicine at Harvard Medical, will lead the scientific work at MGH.

[Read More]

Ethris, AstraZeneca to develop mRNA therapies for respiratory diseases

Tuesday, August 22, 2017

Ethris, a leader in mRNA-based therapeutics with specific expertise in pulmonary disease, announced a five-year strategic research collaboration with AstraZeneca and its global biologics research and development arm, MedImmune. The collaboration is focused on developing new stabilized non-immunogenic modified RNA therapies for respiratory diseases using Ethris’ proprietary SNIM RNA technology.

[Read More]

Champions Oncology, AstraZeneca collaborate

Tuesday, August 22, 2017

Champions Oncology, a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, announced a strategic collaboration with AstraZeneca to develop novel cohorts of PDX models. These models will be used in AstraZeneca’s oncology R&D programs in breast and lung cancer, in addition to being added to Champions’ existing TumorGraft bank for translational oncology research for academic and industry customers. Champions’ global network of collaborating sites will be leveraged to support this multi-year initiative.

[Read More]

Champions Oncology, Addario Lung Cancer Medical Institute partner

Friday, August 18, 2017

Champions Oncology, a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, announced a collaboration with The Addario Lung Cancer Medical Institute (ALCMI) to develop a novel cohort of PDX models in patients with ROS1 gene rearrangement. These models will further expand Champions’ TumorGraft bank offerings in non-small cell lung cancer for translational oncology research for academic and industry customers. Champions’ global infrastructure will be leveraged to support this multi-year program.

[Read More]

Context Therapeutics initiates three research collaborations

Thursday, August 17, 2017

Context Therapeutics, a biotechnology company dedicated to creating new medicines for cancer, fibrosis and neurodegenerative disease, has entered into agreements with three research partners. The company will collaborate with experts in the field of Sigma1 protein and its role in disease biology at the Cedars-Sinai Medical Center, Fred Hutchinson Cancer Research Center and Synergie Lyon Cancer. Context will work with investigators at these institutions to determine the role of Sigma1 in certain animal disease models and to evaluate the activity of its proprietary Sigma1 inhibitors in biopsy explant models, animal models, and human cellular systems.

[Read More]

Takeda, Stanford University announce alliance

Thursday, August 17, 2017

Takeda Pharmaceutical has announced a collaboration with Stanford University to form the Stanford Alliance for Innovative Medicines (Stanford AIM), which will help transform novel Stanford research into next-generation treatments for diseases. Through this unique collaboration, Takeda and Stanford will identify projects on the path to therapeutic discoveries and accelerate the process of bringing these drugs to market to serve patients with unmet needs.

[Read More]